Alector is a clinical-stage biotechnology company working to cure neurodegenerative diseases like Alzheimer’s and frontotemporal dementia (FTD) by harnessing the immune system. Their scientists develop antibody therapies that have reached late-stage trials, bringing real hope to patients and families facing these tough brain disorders.
Alector was founded in 2013 in South San Francisco, California, by a team of scientists and entrepreneurs led by Arnon Rosenthal, Ph.D. They started with $32 million in Series A funding from investors like OrbiMed and Google Ventures, focusing on a new approach: using genetics to guide immune therapies for brain diseases. The company grew through key partnerships, including a 2017 collaboration with AbbVie worth up to $205 million upfront plus milestones for Alzheimer’s targets.
In 2019, Alector went public on Nasdaq (ticker: ALEC), raising $176 million to expand research. They later partnered with GSK in 2021 for up to $2.2 billion in potential value on FTD programs. As of late 2025, their annual R&D spending runs around $238 million, supporting a focused pipeline while adapting to trial costs.
Leadership
Arnon Rosenthal, co-founder and CEO, leads with a science-driven, collaborative style that prioritizes genetically validated targets like progranulin and TREM2 to activate the brain’s immune cells. He builds partnerships, like those with AbbVie and GSK, to share risks and speed progress, making complex trials more efficient through early validation and shared resources. The executive team includes Marc Grasso (CFO) for business strategy, Robert Paul, M.D., Ph.D. (Chief Scientific Officer) for innovation, and Christine Power, M.D. (Chief Medical Officer as of 2025) for clinical oversight, alongside a board with experts like Betta Becker.
This hands-on leadership fosters accountability and teamwork, helping the company navigate challenges efficiently. By focusing on clear priorities and open communication, they streamline projects from lab to trials.
Achievements
Alector’s milestones show their impact on simplifying tough biotech projects. Their lead candidate, latozinemab (AL001), is in Phase 3 trials (INFRONT-3) for FTD with progranulin deficiency, raising protective protein levels in the brain to slow disease. They’ve secured about $300 million in realized collaboration funds, enabling steady advances despite high costs.
Early immuno-oncology research hints at platform expansion, though neurodegeneration remains the core focus. These steps cut trial timelines by targeting proven biology upfront and leveraging partners.
AbbVie partnership 2017 Up to $205M+; validated Alzheimer’s targets
Nasdaq IPO 2019 $176M raised; fueled pipeline growth
GSK deal 2021 Up to $2.2B potential; FTD focus
Phase 3 trials 2025-2026 Latozinemab advancing in INFRONT-3
Personal Values and Plans
Alector’s team brings a patient-first mindset, guided by core values of being bold, accountable, collaborative, and transparent. This approach keeps projects efficient, genetic insights guide fast target selection, while partnerships handle scale. Leaders like Rosenthal emphasize urgency for families, creating a supportive environment where science meets real needs.
Looking ahead in 2026, they aim for key INFRONT-3 data readouts on latozinemab, with about 82% institutional ownership from firms like Vanguard and Fidelity providing stability. Plans center on advancing neurodegeneration therapies toward approval, steadily turning immune science into treatments that ease lives and make drug development smoother for all.
